Skip to main
DBVT

DBVT Stock Forecast & Price Target

DBVT Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

DBV Technologies is a clinical-stage specialty biopharmaceutical company with a strong pipeline and innovative technology platform focused on developing treatments for food allergies, including the potentially game-changing Viaskin Peanut patch. The company has a robust financial position with a cash runway into 2027, providing stability for future growth. While there are clinical, regulatory, and commercial risks involved, DBV has a strong chance of revolutionizing the field of immunotherapy and has potential for significant long-term success, making it a positive investment opportunity.

Bears say

DBV Technologies is facing potential setbacks and delays in their development of Viaskin Peanut, their lead candidate for peanut-allergic patients. These delays include new adverse findings in their ongoing safety study for toddlers and potential competition emerging in the immunotherapy space. Additionally, the company's Viaskin platform has already faced regulatory hurdles, with the FDA requesting additional safety studies. These challenges, combined with the potential for competing treatments, could hinder DBV Technologies' growth potential and stock performance in the long term.

DBVT has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DBV Technologies SA Sponsored ADR (DBVT) Forecast

Analysts have given DBVT a Buy based on their latest research and market trends.

According to 4 analysts, DBVT has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DBV Technologies SA Sponsored ADR (DBVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.